EMD-23899

Single-particle
3.16 Å
EMD-23899 Deposition: 24/04/2021
Map released: 12/05/2021
Last modified: 23/10/2024
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links

EMD-23899

SARS-CoV-2 Spike RBD in complex with neutralizing Fab SARS2-38 (local refinement)

EMD-23899

Single-particle
3.16 Å
EMD-23899 Deposition: 24/04/2021
Map released: 12/05/2021
Last modified: 23/10/2024
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links
Sample Organism: Severe acute respiratory syndrome coronavirus 2, Mus musculus
Sample: SARS-CoV-2 spike bound by SARS2-38 antibody Fab
Fitted models: 7mkm (Avg. Q-score: 0.3)

Deposition Authors: Adams LJ , Fremont DH
A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope.
PUBMED: 34481543
DOI: doi:10.1016/j.immuni.2021.08.016
ISSN: 1074-7613
ASTM: IUNIEH
Abstract:
With the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with increased transmissibility and potential resistance, antibodies and vaccines with broadly inhibitory activity are needed. Here, we developed a panel of neutralizing anti-SARS-CoV-2 monoclonal antibodies (mAbs) that bound the receptor binding domain of the spike protein at distinct epitopes and blocked virus attachment to its host receptor, human angiotensin converting enzyme-2 (hACE2). Although several potently neutralizing mAbs protected K18-hACE2 transgenic mice against infection caused by ancestral SARS-CoV-2 strains, others induced escape variants in vivo or lost neutralizing activity against emerging strains. One mAb, SARS2-38, potently neutralized all tested SARS-CoV-2 variants of concern and protected mice against challenge by multiple SARS-CoV-2 strains. Structural analysis showed that SARS2-38 engaged a conserved epitope proximal to the receptor binding motif. Thus, treatment with or induction of neutralizing antibodies that bind conserved spike epitopes may limit the loss of potency of therapies or vaccines against emerging SARS-CoV-2 variants.